Asimov and RevOpsis Therapeutics sign licensing agreement for high titer multispecific-expressing…
Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System with RevOpsis Therapeutics ("RevOpsis"), a next-generation…
Read More...
Read More...